Latest Market Entry News

LTR Pharma has formalised its US commercialisation strategy by signing a definitive agreement with telehealth leader Shed, targeting at least 150,000 ROXUS units in the first year through digital men’s health platforms.

Memphasys delivered a record $150,000 quarterly revenue, secured its largest Felix™ supply contract with Monash IVF, and expanded into UK and Southeast Asian IVF markets, positioning for accelerated growth in FY27.

Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.

Botanix Pharmaceuticals has received an Intention to Grant from the European Patent Office for a patent protecting its Sofdra applicator technology, potentially extending exclusivity in Europe until 2039.

Swift TV has landed a second multi-site hospitality contract, expanding its footprint in premium Western Australian accommodation and reinforcing its recurring revenue model.

ReNerve Limited has secured regulatory approval to market its flagship NervAlign Nerve Cuff in Indonesia, marking a major step in its Asia-Pacific expansion and unlocking access to one of the region’s largest nerve repair markets.

Germany’s Hesse State Office has issued new GMP guidance that questions the viability of fragmented medicinal cannabis supply chains, reinforcing ECS Botanics’ integrated manufacturing approach and potentially tightening market supply.

Orthocell has secured a strategic foothold in Thailand's $84 million nerve repair sector by appointing MediTime as exclusive Remplir distributor, leveraging established clinical networks to accelerate market penetration.

Gold Hydrogen gears up for critical Ramsay Project flow testing of Natural Hydrogen and Helium, while advancing a green methanol feasibility study with Mitsubishi Gas Chemical.

Intelligent Monitoring Group (ASX:IMB) has agreed to acquire ADT's UK residential security business for GBP 180 million, doubling its scale and entering a fast-growing market. The deal is expected to add 40% to EPS on a pro forma basis without requiring external equity.

Iperion Limited trimmed its net loss to $294,595 for the year to March 2026, aided by waived manufacturing fees and waived licence performance targets, while securing a $250,000 loan facility to underpin ongoing development of its antimicrobial Pathoglaze product.

AnteoTech has shipped a 20-litre sample of its new Anteo C primer coating additive to a South Korean manufacturer, marking a key step from lab trials to manufacturing-scale evaluation in lithium-ion battery production.